On Monday, Novo Nordisk (NOVOb.CO) said it would invest 15.9 billion Danish crowns ($2.29 billion) to develop a Danish production facility for serious chronic disease treatments.
The facility will expand to create active pharmaceutical ingredients (API), the key biologically active components of medications, for present and future goods.
A spokeswoman informed Reuters that Novo’s popular diabetes and weight-loss medications Ozempic and Wegovy’s core ingredient, semaglutide, is not being produced.
After overwhelming demand for Wegovy during its 2021 US launch, Novo has invested heavily to boost semaglutide supplies.
Last month, the company announced it would ration Wegovy beginning doses in the US to meet demand.
The new factory will start producing API in early 2029 after construction.
“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Novo’s head of product supply, quality, and IT, Henrik Wulff.
Novo, which makes API in two sites in Denmark and one in Clayton, North Carolina, announced last year that it would invest 5.4 billion crowns in developing its Bagsvaerd facilities.
